NCT02233075View on ClinicalTrials.gov

REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

November 30, 2016

Study Completion Date

May 31, 2017

Conditions
Chronic HBV Infection (HBeAg Negative)
Interventions
DRUG

REP 2139-Ca + Pegasys (TM)

15 weeks of REP 2139-Ca (500mg QW IV) followed by: 15 weeks of REP 2139-Ca (250mg QW IV) + Pegasys(TM) (180 ug QW SC) followed by: 33 weeks of Pegasys(TM) (180 ug QW SC)

Trial Locations (1)

2004

Infectious Clinical Hospital ( n.a. Toma Ciorba), Chisinau

All Listed Sponsors
lead

Replicor Inc.

INDUSTRY

NCT02233075 - REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection | Biotech Hunter | Biotech Hunter